Breaking Finance News

Zacks Investment Research downgraded GlaxoSmithKline plc (ADR) (NYSE:GSK) to Sell in a statement released earlier today.

Zacks Investment Research has downgraded GlaxoSmithKline plc (ADR) (NYSE:GSK) to Sell in a statement released on 10/05/2016.

On 9/27/2016, Zacks Investment Research released a statement on GlaxoSmithKline plc (ADR) (NYSE:GSK) increased the target price from $0.00 to $48.00. At the time, this indicated a possible upside of 0.12%.

Having a price of $43.33, GlaxoSmithKline plc (ADR) (NYSE:GSK) traded -0.25% lower on the day. With the last close up 1.16% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. The company has recorded a 50-day moving average of $43.52 and a two hundred day average of $42.83. Volume of trade was down over the average, with 2,087,236 shares of GSK changing hands under the typical 2,797,680

Recent Performance Chart

GlaxoSmithKline plc (ADR) (NYSE:GSK)

GlaxoSmithKline plc (ADR) has one year low of $37.82 and a one year high of $45.58 with a P/E ratio of 2,708.12 and has a market capitalization of $0.

Also covering GlaxoSmithKline plc (ADR)'s target, a total of 3 brokerages have issued a ratings update on the stock. The consensus target price is $47.33 with 2 brokers rating the stock a strong buy, 0 firms rating the stock a buy, 2 firms rating the company a hold, zero equity analysts rating the stock a underperform, and finally 0 analysts rating the company a sell.

General Company Details For GlaxoSmithKline plc (ADR) (NYSE:GSK)

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company's segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals business develops and makes medicines to treat a range of acute and chronic diseases. The Vaccines business develops, produces and distributes over 1.9 million vaccines every day to people across the world. The Consumer Healthcare business develops and markets products in various categories, such as Wellness, Oral health, Nutrition and Skin health. The Pharmaceuticals Research and Development (R&D) focuses on the discovery and development in various areas of research, which include human immunodeficiency virus (HIV) and infectious diseases, oncology, immuno-inflammation, respiratory and rare diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.